Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

ZYNLONTA

LONCASTUXIMAB TESIRINE-LPYL

Standard Dose
10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ZYNLONTA is listed in Drugs@FDA under application 761196 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LONCASTUXIMAB TESIRINE-LPYL Form and strength INJECTABLE;INJECTION - 10MG Sponsor ADC Therapeutics SA Submission history Latest submission status date: 2026-02-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZYNLONTA is listed in Drugs@FDA under application 761196 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient LONCASTUXIMAB TESIRINE-LPYL Form and strength INJECTABLE;INJECTION - 10MG Sponsor ADC Therapeutics SA Submission history Latest submission status date: 2026-02-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.